Page 27 - P4304.1-V94_PS-Magazine-February 2024 PRINT
P. 27

Helping your patients live   Tips from your


 in harmony with creatures

 great and small  Live like you  Dispensing Doctor


 Ryaltris is indicated in adults and
 adolescents 12 years of age and older
 for the treatment of moderate to   Account Manager
 severe nasal symptoms associated
 with allergic rhinitis (AR). 1
        Julie Darley,


        DDAM for East of England



        Julie Darley is one of PSUK most experienced account
        managers, working with dispensing practices for over 37
        years  and supporting PSUK members for over 10 years
        saving money and improving dispensary profits.   This
        month Julie shares some of her insights and top tips
        that are often discussed with her customers.

        With over 100 years of total experience, working solely with
        dispensing practices, the PSUK account manager team are far
        more than just average account managers. We have first-hand
 Ryaltris  combination intranasal spray can bring symptom   market insight, commercial knowledge and provide extensive
 ®
 relief within 10-15 minutes* from allergic rhinitis triggered by   information enabling you to make well informed balanced
        decisions, supporting your drive for efficiency savings, compliance
 perennial factors such as animal dander and dust mites. 1-4  improvement and increased margin. Our approach to account
 *Findings from one environmental exposure chamber study and two large randomised controlled trials. 2-4  management fully supports our PSUK mantra of ‘Conquering
 Ryaltris is generally well tolerated; the most commonly-reported adverse reactions are dysgeusia,   tomorrow together’.
 epistaxis and nasal discomfort. 1,2,5
 Scan to visit
 Find out more at www.ryaltris.co.uk  www.ryaltris.co.uk  Your practice will no doubt have recently reviewed your 22/23
        annual accounts which hopefully, will have shown to be healthy!
        However, considering the current economic climate that everyone

 Ryaltris Prescribing Information  during periods of stress or elective surgery. The replacement of a systemic corticosteroid   will be facing in their personal lives, you may have seen a slight
 Ryaltris  (mometasone  furoate  and  olopatadine  hydrochloride)  Please  refer  to  the  with a topical corticosteroid can be accompanied by signs of adrenal insufficiency, and
 Summary of Product Characteristics (SmPC) before prescribing. One delivered dose   some patients may experience symptoms of withdrawal. Patients previously treated for   decline in practice profit. This is where PSUK account managers
 contains mometasone furoate monohydrate equivalent to 25 microgram mometasone   prolonged periods with systemic corticosteroids and transferred to topical corticosteroids
 furoate  and  olopatadine  hydrochloride  equivalent  to  600  micrograms  olopatadine.   should  be  carefully  monitored  for  acute  adrenal  insufficiency  in  response  to  stress.   come into their own and demonstrate that we are more than
 Indication:  treatment  of  moderate  to  severe  nasal  symptoms  associated  with  allergic   In  those  patients  who  have  asthma  or  other  clinical  conditions  requiring  long  term
 rhinitis  in  adults  and  adolescents  12  years  of  age  and  older  Posology  and  method  of  systemic corticosteroid treatment, too rapid a decrease in systemic corticosteroids may   just a wholesaler moving boxes.
 administration:  The  usual  recommended  dose  is  two  actuations  in  each  nostril  twice   cause a severe exacerbation of their symptoms. Somnolence: in isolated cases dizziness,
 daily  (morning  and  evening).  Children  below  12  years:  Ryaltris  is  not  recommended.   lethargy,  fatigue  and  somnolence  may  occur  when  using  Ryaltris.  In  these  cases,  the
 Elderly: No dose adjustment required. Renal and hepatic impairment: there are no data   ability to drive and use machines may be impaired. Alcohol and other CNS depressants
 in patients with renal and hepatic impairment, however no dose adjustment is expected   may enhance this effect. Antihistamine effects: concomitant use of other antihistaminic
 to be required. Contraindications: Hypersensitivity to the active substances or to any of   drugs  administered  may  increase  the  risk  of  antihistamine  adverse  effects.  Paediatric
 the excipients. Ryaltris should not be used in the presence of untreated localised infection   population: It is recommended that the height of children receiving prolonged treatment
 involving the nasal mucosa, such as herpes simplex. Patients who have experienced recent   with nasal corticosteroids is regularly monitored. If growth is slowed, therapy should be
 nasal surgery or trauma should not use a nasal corticosteroid until healing has occurred.   reviewed with the aim of reducing the dose of nasal corticosteroid if possible, to the lowest
 Precautions: Local nasal effects: nasal ulceration and nasal septal perforation have been   dose at which effective control of symptoms is maintained. Excipients: Ryaltris contains     How can PSUK assist you to
 reported in patients following intranasal antihistamines. Nasal septal perforation has been   0.02  mg  benzalkonium  chloride  in  each  actuation.  Benzalkonium  chloride  may  cause
 reported following intranasal corticosteroids. Patients using Ryaltris over several months   irritation or swelling inside the nose, especially if used for a long time. Adverse reactions:
 or  longer  should  be  examined  periodically  for  possible  changes  in  the  nasal  mucosa.   Common  (≥1/100  to  <1/10):  dysgeusia  (unpleasant  taste),  epistaxis,  nasal  discomfort.   reduce any losses?
 Ryaltris is not recommended in cases of nasal septum perforation. In clinical studies with   Uncommon  (≥1/1,000  to  <1/100):  dizziness,  headaches,  somnolence,  nasal  dryness,  dry
 mometasone furoate administered intranasally, the development of localised infections   mouth, abdominal pain, nausea, fatigue. Rare (≥1/10,000 to <1/1000) bacterial vaginosis,
 of the nose and pharynx with Candida albicans has occurred; may require treatment and   anxiety, depression, insomnia, lethargy, migraine, blurred vision, dry eye, eye discomfort,   The first thing to note is that the NHS contract is
 discontinuation of Ryaltris. Patients using Ryaltris over several months or longer should be   ear  pain,  nasal  inflammation,  nasal  mucosal  disorder,  oropharyngeal  pain,  sneezing,
 examined periodically for evidence of Candida infection or other signs of adverse effects   throat  irritation,  constipation,  sore  tongue,  laceration.  Incidence  not  known  (reported   fundamentally set up to allow practices to make a
 on  the  nasal  mucosa.  Visual  disturbances  may  be  reported  with  systemic  and  topical   from use of corticosteroids): pharyngitis, upper respiratory tract infection, hypersensitivity
 corticosteroid use. Symptoms such as blurred vision or other visual disturbances should   including anaphylactic reactions, angioedema, bronchospasm, and dyspnoea, cataracts,   profit on their generic purchases, with PSUK you will
 be  considered  for  ophthalmologist  referral  for  evaluation  of  possible  causes  including   glaucoma,  increased  intraocular  pressure,  nasal  septum  perforation.  Marketing
 cataract,  glaucoma  or  rare  diseases  such  as  central  serous  chorioretinopathy  (CSCR).   authorisation number: PL 25258/0331 Marketing Authorisation Holder and distributer:   always make money on your generic basket due to
 Hypersensitivity  Reactions  including  instances  of  wheezing,  may  occur.  Discontinue   Glenmark  Pharmaceuticals  Europe  Limited,  Laxmi  House,  2B  Draycott  Avenue
 Ryaltris  if  such  reactions  occur.  Immunosuppression:  Chickenpox  and  measles,  for   Kenton,  Middlesex,  HA3  0BU.  United  Kingdom  Legal  classification:  POM  Cost:  £13.32.     our market leading APM proposition. Where losses
 example, can have a more serious or even fatal course in susceptible patients and those   1  bottle  with  29  g  suspension  (240  actuations)  Date  of  preparation:  June  2021.  Job
 using  corticosteroids.  In  children  or  adults  who  have  not  had  these  diseases  or  been   number: PP-UK-RYAL-0001  tend to occur is predominantly on the branded side
 properly immunized, particular care should be taken to avoid exposure. Corticosteroids
 should  be  used  with  caution,  if  at  all,  in  patients  with  active  or  quiescent  tuberculous   Adverse events should be reported. Reporting forms and information    of your purchasing due to clawback, it is crucial that
 infections of the respiratory tract, untreated local or systemic fungal or bacterial infections,   can be found at https://yellowcard.mhra.gov.uk. Adverse events should
 systemic viral or parasitic infections, or ocular herpes simplex because of the potential   also be reported to Glenmark Pharmaceuticals Europe Ltd    you minimise those losses through discounts/rebates
 for worsening of these infections. Systemic Effects of Corticosteroids: potential systemic
 effects  may  include  Cushing’s  syndrome,  Cushingoid  features,  adrenal  suppression,   medical_information@glenmarkpharma.com or call 0800 458 0383  and potentially prescribing changes which we can
 growth retardation in children and adolescents, cataract, glaucoma and more rarely, a
 range of psychological or behavioural effects including psychomotor hyperactivity, sleep   References: 1. Ryaltris Summary of Product Characteristics. 2. Gross GN, et al. Ann   advise on through or loss-making line reports.
 disorders,  anxiety,  depression  or  aggression  (particularly  in  children).  When  intranasal   Allergy Asthma Immunol 2019;122:630–638. 3. Hampel FC, et al. Allergy Asthma Proc
 steroids  are  used  at  higher  than  recommended  dosages  or  in  susceptible  individuals   2019;40(4):261–272. 4. Patel P, et al. Ann Allergy Asthma Immunol 2019;122(2):160–166.
 at  recommended  dosages,  systemic  corticosteroid  effects  such  as  hypercorticism  and   5. Segall N, et al. Allergy Asthma Proc 2019;40:301-310.
 adrenal  suppression  may  appear.  If  such  changes  occur,  the  dosage  of  Ryaltris  should
 be  discontinued  slowly,  consistent  with  accepted  procedures  for  discontinuing  oral   Ryaltris  is a registered trademark of Glenmark Speciality S.A.
 ®
 corticosteroid  therapy.  The  concomitant  use  of  intranasal  corticosteroids  with  other
 inhaled corticosteroids could increase the risk of signs or symptoms of hypercorticism   © 2023 Glenmark Pharmaceuticals Europe Ltd.
 and/or suppression of the HPA axis. If there is evidence for higher than recommended   All rights reserved.
 doses  being  used,  then  additional  systemic  corticosteroid  cover  should  be  considered   Date of preparation: October 2023  PP-UK-RYAL-0338 V1
                                                                                                              27
         or call us on 01904 558 350                                   Top tips from your DDAM | PS Magazine   27
 020006_AW_Ryaltris_PSUK_210x297mm.indd   1  30/10/2023   09:34
 30/10/2023   09:34
 020006_AW_Ryaltris_PSUK_210x297mm.indd   1
   22   23   24   25   26   27   28   29   30   31   32